New treatments in age-related macular degeneration

Clinical and Experimental Ophthalmology

Volumn 31, Issue 5, 2003, Pages 376-391

  Hooper, Claire Y ^a   Guymer, Robyn H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Age related macular degeneration; Choroidal neovascularization; New treatments

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA INTERFERON; ALPHA2A INTERFERON; ANECORTAVE; ANGIOGENESIS INHIBITOR; ANGIOSTATIC AGENT; BENZOPORPHYRIN DERIVATIVE; FLUOCINOLONE ACETONIDE; FLUOROCARBON; LUTETIUM TEXAPHYRIN; PEGAPTANIB; PLACEBO; STEROID; THALIDOMIDE; TIN ETHYL ETIOPURPURIN; TISSUE PLASMINOGEN ACTIVATOR; TRIAMCINOLONE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; AGING; BACKACHE; BLINDNESS; BRACHYTHERAPY; CATARACT; CATARACT EXTRACTION; CELL TRANSPLANTATION; CHEMOSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIPLOPIA; DOSE CALCULATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; EYE SURGERY; EYELID EDEMA; FIBRINOLYSIS; HEALTH CARE COST; HUMAN; HYPERTHERMIC THERAPY; IATROGENIC DISEASE; INJECTION PAIN; INTRAOCULAR HEMORRHAGE; INTRAOCULAR PRESSURE ABNORMALITY; IRRADIATION; KERATOCONJUNCTIVITIS; LASER COAGULATION; NONHUMAN; OPTIC NERVE DISEASE; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION RESPONSE; RETINA DETACHMENT; RETINA INJURY; RETINA MACULA DEGENERATION; RETINA MACULA EDEMA; RETINA MACULA HEMORRHAGE; RETINA MACULA TRANSLOCATION; RETINA PIGMENT DEGENERATION; RETINOPATHY; RETINOTOMY; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SUBRETINAL NEOVASCULARIZATION; SYSTEMIC DISEASE; TREATMENT INDICATION; VISUAL DISORDER; VITRECTOMY; VITREORETINOPATHY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; HUMANS; HYPERTHERMIA, INDUCED; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PIGMENT EPITHELIUM OF EYE; RETINA; RETINAL HEMORRHAGE; STEROIDS;

EID: 0344468121     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2003.00683.x     Document Type: Review

References (178)

1. VanNewkirk MR, Weih L, McCarty CA, Taylor HR. Cause-specific prevalence of bilateral visual impairment in Victoria, Australia: The Visual Impairment Project. Ophthalmology 2001; 108: 960-7.
2. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996; 103: 357-64.
3. Klein R, Wang Q, Klein BEK, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci 1995; 36: 182-91.
4. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32: 375-413.
5. Mitchell P, Smith W, Attebo K, Wang J. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology 1995; 102: 1450-60.
6. VanNewkirk MR, Nanjan MB, Wang JJ, Mitchell P, Taylor HR, McCarty CA. The prevalence of age-related maculopathy: The Visual Impairment Project. Ophthalmology 2000; 107: 1593-600.
7. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-43.
8. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989; 107: 847-52.
9. Vingerling JR, Dielemans I, Hofman A et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 1995; 102: 205-10.
10. Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthamol 2000; 118: 264-9.
11. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-2.
12. Freund KB, Yannuzzi LA, Sorensen JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993; 115: 786-91.
13. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31.
14. Macular Photocoagulation Study Group. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1986; 104: 503-12.
15. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Arch Ophthalmol 1994; 112: 480-8.
16. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991; 109: 1242-57.
17. Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: The role of ophthalmologists. Ophthalmologica 2001; 215: 247-53.
18. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
19. Husain D, Miller JW. Photodynamic therapy of exudative age-related macular degeneration. Semin Ophthalmol 1997; 12: 14-25.
20. Donati G, Kapetanios AD, Pournaras CJ. Principles of treatment of choroidal neovascularisation with photodynamic therapy in age-related macular degeneration. Semin Ophthalmol 1999; 14: 2-10.
21. Ghazi NG, Jabbour NM, De La Cruz ZC, Green WR. Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 2001; 21: 478-86.
22. Schmidt-Erfurth U. Indocyanine green angiography and retinal sensitivity after photodynamic therapy for subfoveal choroidal neovascularization. Semin Ophthalmol 1999; 14: 35-44.
23. Bressler NM, Bressler SB. Photodynamic therapy with verteportin (Visudyne): Impact on ophthalmology and visual sciences. Invest Ophthalmol Vis Sci 2000; 41: 624-8.
24. Soubrane G, Bressler NM. Treatment of subfoveal choroidal neovascularisation in age-related macular degeneration: Focus on clinical application of verteporfin photodynamic therapy. Br J Ophthalmol 2001; 85: 483-95.
25. Miller JW, Schmidt-Erfurth U, Sickenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1161-73.
26. Schmidt-Erfurth U, Miller JW, Sickenberg M et al. Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macula degeneration. Results of retreatments in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177-87.
27. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. One year results of two randomized clinical trials - TAP report 1. Arch Ophthalmol 1999; 117: 1329-45.
28. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Two year results of two randomized clinical trials - TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
29. Margherio RR, Margherio AR, DeSantis ME. Laser treatments with verteporfin therapy and its potential impact on retinal practices. Retina 2000; 20: 325-30.
30. Bressler NM, Gills JP. Age related macular degeneration. New hope for a common problem comes from photodynamic therapy. BMJ 2000; 321: 1425-7.
31. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy for subfoveal choroidal neovascularisation in age-related macular degeneration: Two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularisation - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
32. Yonemoto LT, Slater JD, Friedrichsen EJ et al. Phase I/II study of proton beam irradiation for the treatment of subfoveal choroidal neovascularisation in age-related macular degeneration: Treatment techniques and preliminary results. Int J Radiat Oncol Biol Phys 1996; 36: 867-71.
33. Flaxel CJ, Freidrichsen EJ, Smith JO et al. Proton beam irradiation of subfoveal choroidal neovascularisation in age-related macular degeneration. Eye 2000; 14: 155-64.
34. Chakravarthy U. Radiotherapy for choroidal neovascularisation of age-related macular degeneration: A fresh perspective. Eye 2000; 14: 151-4.
35. Finger PT, Berson A, Sherr D, Riley R, Balkin RA, Bosworth JL. Radiation therapy for subretinal neovascularisation. Ophthalmology 1996; 103: 878-89.
36. Finger PT, Berson A, Ng T, Szechter A. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularisation. Am J Ophthalmol 1999; 127: 170-7.
37. Gelisken O, Yazici B. Radiation therapy in exudative age-related macular degeneration. Semin Ophthalmol 1999; 14: 27-34.
38. Chakravarthy U, Houston RF, Archer DB. Treatment of age-related subfoveal neovascular membranes by teletherapy: A pilot study. Br J Ophthalmol 1993; 77: 265-73.
39. Ciulla TA, Danis RP, Harris A. Age-related macular degeneration: A review of experimental treatments. Surv Ophthalmol 1998; 43: 134-46.
40. Chakravarthy U, Gardiner TA, Archer DB, Maguire CJ. A light microscopic and autoradiographic study of non-irradiated and irradiated ocular wounds. Curr Eye Res 1989; 8: 337-48.
41. Chakravarthy U, Biggart JH, Gardiner TA, Archer DB, Maguire CJ. Focal irradiation of perforating eye injuries. Curr Eye Res 1989; 8: 1241-50.
42. Hart PM, Archer DB, Chakravarthy U, Asymmetry of disciform scarring in bilateral disease when one eye is treated with radiotherapy. Br J Ophthalmol 1995; 79: 562-8.
43. Hart PM, Chakravarthy U, MacKenzie G, Archer DB, Houston RF. Teletherapy for subfoveal choroidal neovascularisation of age-related macular degeneration: Results of follow up in a non-randomised study. Br J Ophthalmol 1996; 80: 1046-50.
44. Hollick EJ, Goble RR, Knowles PJ, Ramsey MC, Deutsch G, Casswell AG. Radiotherapy treatment of age-related subfoveal neovascular membranes in patients with good vision. Eye 1996; 10: 609-16.
45. Freire J, Longton WA, Miyamoto CT et al. External radiotherapy in macular degeneration: Technique and preliminary subjective response. Int J Radiat Oncol Biol Phys 1996; 36: 857-60.
46. Berson AM, Finger PT, Sherr DL, Emery R, Alfieri AA, Bosworth JL. Radiotherapy of age-related macular degeneration: Preliminary results of a potentially new treatment. Int J Radiat Oncol Biol Phys 1996; 36: 861-5.
47. Akmansu M, Dirican B, Ozturk B, Egehan I, Subasi M, Or M. External radiotherapy in macular degeneration: Our technique, dosimetric calculation, and preliminary results. Int J Radiat Oncol Biol Phys 1998; 40: 923-7.
48. Postgens H, Bodanowitz S, Kroll P. Low-dose radiation therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1997; 235: 656-61.
49. Spaide RF, Guyer DR, McCormick B et al. External beam radiation therapy for choroidal neovascularisation. Ophthalmology 1998; 105: 24-30.
50. Stalmans P, Leys A, Van Limbergen E. External beam radiotherapy (20 Gy, 2 Gy fractions) fails to control the growth of choroidal neovascularisation in age-related macular degeneration: A review of 111 cases. Retina 1997; 17: 481-92.
51. Krott R, Staar S, Muller R, Bartz-Schmidt KU, Esser P, Heimann K. External beam radiation in patients suffering from exudative age-related macular degeneration. A matched-pairs study and 1-year clinical follow-up. Graefes Arch Clin Exp Ophthalmol 1998; 236: 916-21.
52. The Radiation Therapy for Age-related Macular Degeneration Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 1999; 106: 2239-47.
53. Marcus DM, Sheils C, Johnson MH et al. External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration. One year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol 2001; 119: 171-80.
54. Valmaggia C, Ries G, Ballinari P. Radiotherapy for subfoveal choroidal neovascularization in age-related macular degeneration: A randomized clinical trial. Am J Ophthalmol 2002; 133: 521-9.
55. Kobayashi H, Kobayashi K. Age-related macular degeneration: Long-term results of radiotherapy for subfoveal neovascular membranes. Am J Ophthalmol 2000; 130: 617-35.
56. Bergink GJ, Hoyng CB, Van Der Maazen RWM, Vingerling JR, Van Daal WAJ, Deutman AF. A randomized controlled clinical trial on the efficacy of radiation therapy in the control of subfoveal choroidal neovascularization in age-related macular degeneration: Radiation versus observation. Graefes Arch Clin Exp Ophthalmol 1998; 236: 321-5.
57. Char DH, Irvine AI, Posner MD, Quivey JQ, Phillips TL, Kroll S. Randomized trial of radiation for age-related macular degeneration. Am J Ophthalmol 1999; 127: 574-8.
58. Mauget-Faysse M, Chiquet C, Milea D et al. Long term results of radiotherapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol 1999; 83: 923-8.
59. Bergink GJ, Deutman AF, Van Den Broek JF, Van Daal WA, Van Der Maazen RW. Radiation therapy for subfoveal choroidal neovascular membranes in age-related macular degeneration. A pilot study. Graefes Arch Clin Exp Ophthalmol 1994; 232: 591-8.
60. Spaide RF, Leys A, Herrmann-Delemazure B et al. Radiation-associated choroidal neovasculopathy. Ophthalmology 1999; 106: 2254-60.
61. Fine SL, Maguire MG. It is not time to abandon radiotherapy for neovascular age-related macular degeneration. Arch Ophthalmol 2001; 119: 275-6.
62. Mainster MA, Reichel E. Transpupillary thermotherapy for age-related macular degeneration: Long-pulse photocoagulation, apoptosis, and heat shock proteins. Ophthalmic Surg Lasers 2000; 31: 359-73.
63. Ip M, Kroll A, Reichel E. Transpupillary thermotherapy. Semin Ophthalmol 1999; 14: 11-18.
64. Oosterhuis JA, Journee-De Korver HG, Kakebeeke-Kemme HM, Blecker JC. Transpupillary thermotherapy in choroidal melanomas. Arch Ophthalmol 1995; 113: 315-21.
65. Shields CL, Shields JA, Cater J et al. Transpupillary thermotherapy for choroidal melanoma: Tumor control and visual results in 100 consecutive cases. Ophthalmology 1998; 105: 581-90.
66. Godfrey DG, Waldron RG, Capone A Jr. Transpupillary thermotherapy for small choroidal melanoma. Am J Ophthalmol 1999; 128: 88-93.
67. Robertson DM, Buettner H, Bennett SR. Transpupillary thermotherapy as primary treatment for small choroidal melanomas. Arch Ophthalmol 1999; 117: 1512-19.
68. Desai V, Reichel E, Kroll A, Duker J, Puliafito C. Transpupillary thermotherapy of subfoveal choroidal neovascularisation in age-related macular degeneration. Invest Ophthalmol Vis Sci 1998; 39 (Suppl.): S385.
69. Reichel E, Berrocal AM, Ip M et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999; 106: 1908-14.
70. Tang J, Ferrone PJ, Harrison SA et al. The use of transpupillary thermotherapy for the treatment of wet age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42 (Suppl.): S442.
71. Ahuja RM, Schwartz JC, Butler JW, Steidl SM, Benner JD. Efficacy of transpupillary thermotherapy in the treatment of occult subfoveal choroidal neovascularisation in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42 (Suppl.): S443.
72. Bressler NM, Frost LA, Bressler SB, Murphy RP, Fine SL. Natural course of poorly defined choroidal neovascularization associated with macular degeneration. Arch Ophthalmol 1988; 106: 1537-42.
73. Newsom R, McAlister JC, Saeed M, McHugh JD. Transpupillary thermotherapy for the treatment of choroidal neovascularisation. Br J Ophthalmol 2001; 85: 173-8.
74. Thompson JT. Retinal pigment epithelial tear after transpupillary thermotherapy for choroidal neovascularization. Am J Ophthalmol 2001; 131: 662-4.
75. Sanders JB, Cummings H, McMillan T et al. Treatment of predominantly occult subfoveal choroidal neovascularisation secondary to age-related macular degeneration with transpupillary thermotherapy. Invest Ophthalmol Vis Sci 2001; 42 (Suppl.): S513.
76. Benner JD, Ahuja RM, Schwartz JC, Butler JW, Steidl SM. Macular infarction after transpupillary thermotherapy in the treatment of occult subfoveal choroidal neovascular membranes. Invest Ophthalmol Vis Sci 2001; 42 (Suppl.): S444.
77. Wells JA, Murthy R, Chibber R et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80: 363-6.
78. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154-62.
79. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-68.
80. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-44.
81. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
82. Adamis AP, Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischaemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
83. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LEH. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA 1995; 92: 905-9.
84. Miller JW, Adamis AP, Shima DT et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
85. Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal vascularisation in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-61.
86. Malecaze F, Clamens S, Simorre-Pinatel V et al. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch Ophthalmol 1994; 112: 1476-82.
87. Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: Relationship to endothelial dysfunction and laser treatment. Invest Ophthalmol Vis Sci 2000; 41: 2115-19.
88. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-34.
89. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
90. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology 2001; 108: 705-10.
91. Guyer D. The role of vascular endothelial growth factor (VEGF) in the pathogenesis of age-related macular degeneration. Clin Experiment Ophthalmol 2002; 30 (Suppl.): A61.
92. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
93. Kaven C, Spraul CW, Zavazava N, Lang GK, Lang GE. Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro. Ophthalmologica 2001; 215: 284-9.
94. McCarty MF. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis. Med Hypotheses 1997; 49: 123-31.
95. Thomas MA, Ibanez HE. Interferon alfa-2a in the treatment of subfoveal choroidal neovascularisation. Am J Ophthalmol 1993; 115: 563-8.
96. Guyer DR, Adamis AP, Gragoudas ES, Folkman J, Slakter JS, Yannuzzi LA. Systemic antiangiogenic therapy for choroidal neovascularization: What is the role of interferon alpha? Arch Ophthalmol 1992; 110: 1383-4.
97. Poliner LS, Tornambe PE, Michelson PE, Heitzmann JG. Interferon alpha-2a for subfoveal neovascularization in age-related macular degeneration. Ophthalmology 1993; 100: 1417-24.
98. Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch Ophthalmol 1997; 115: 865-72.
99. Miller JW, Stinson WG, Folkman J. Regression of experimental iris neovascularization with systemic alpha-interferon. Ophthalmology 1993; 100: 9-14.
100. Fung WE. Interferon alfa-2a for treatment of age-related macular degeneration. Am J Ophthalmol 1991; 112: 349-50.
101. Engler CB, Sander B, Koefoed P, Larsen M, Vinding T, Lung-Andersen H. Interferon alfa-2a treatment of patients with subfoveal neovascular macular degeneration: A pilot investigation. Acta Ophthalmol 1993; 71: 27-31.
102. Gillies MC, Sarks JP, Beaumont PE et al. Treatment of choroidal neovascularisation in age-related macular degeneration with interferon alfa-2a and alfa-2b. Br J Ophthalmol 1993; 77: 759-65.
103. Lewis ML, Davis J, Chuang E. Interferon alfa-2a in the treatment of exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1993; 231: 615-18.
104. Loughnan MS, Heriot WJ, O'Day J. Treatment of subfoveal choroidal neovascular membranes with systemic interferon-α 2a. Aust NZ J Ophthalmol 1992; 20: 173-5.
105. Chan CK, Kempin SJ, Noble SK, Palmer GA. The treatment of choroidal neovascular membranes by alpha interferon. An efficacy and toxicity study. Ophthalmology 1994; 101: 289-300.
106. Jaakkola A, Anttila PM, Immonen I. Interferon alpha-2a in the treatment of exudative senile macular degeneration. Acta Ophthalmol 1994; 72: 545-9.
107. Thoelen A, Menozzi M, Huber C, Messmer E. Treatment of choroidal neovascularization in age-related macular degeneration with interferon alpha-2a: A short term, nonrandomized pilot study. Ger J Ophthalmol 1995; 4: 137-43.
108. Kirkpatrick JN, Dick AD, Forrester JV. Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. Br J Ophthalmol 1993; 77: 766-70.
109. Engler C, Sander B, Villumsen J, Lund-Andersen H. Interferon alfa-2a modifies the course of subfoveal and juxtafoveal choroidal neovascularisation. Br J Ophthalmol 1994; 78: 749-53.
110. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust NZ J Ophthalmol 1995; 23: 293-8.
111. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-50.
112. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985; 103: 708-11.
113. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor ABL, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow up. Aust NZ J Ophthalmol 1998; 26: 277-81.
114. Gillies M, Simpson J, Luo W et al. The efficacy and safety of a single intravitreal injection of triamcinolone for neovascular age-related macular degeneration. One year results of a randomised clinical trial: IVTAS. Clin Experiment Ophthalmol 2002; 30 (Suppl.): A64.
115. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust NZ J Ophthalmol 1999; 27: 431-2.
116. Soubrane G. Baseline patient characteristics and current status of clinical studies with anecortave acetate in AMD. Clin Experiment Ophthalmol 2002; 30 (Suppl.): A66.
117. Przydryga J, Duzee B, Robertson S, Collier R, Clark A, Slakter J. Anecortave acetate: Pharmacology of a unique ocular angiostatic agent. Clin Experiment Ophthalmol 2002; 30: (Suppl.): A66.
118. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage involving the fovea. Am J Ophthalmol 1990; 109: 33-7.
119. Berrocal MH, Lewis ML, Flynn HW Jr. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 1996; 122: 486-93.
120. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996; 16: 183-9.
121. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982; 94: 762-73.
122. Toth CA, Morse LS, Hjelmeland LM, Landers III MB. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991; 109: 723-9.
123. Lewis H, Resnick SC, Flannery JG, Straatsma BR. Tissue plasminogen activator treatment of experimental subretinal hemorrhage. Am J Ophthalmol 1991; 111: 197-204.
124. Coll GE, Sparrow JR, Marinovic A, Chang S. Effect of intravitreal tissue plasminogen activator on experimental subretinal hemorrhage. Retina 1995; 15: 319-26.
125. Krepler K, Kruger A, Tittl M, Stur M, Wedrich A. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by aged-related macular degeneration. Retina 2000; 20: 251-6.
126. De Juan E Jr., Machemer R. Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 1988; 105: 25-9.
127. Wade EC, Flynn HW Jr., Olsen KR, Blumenkranz MS, Nicholson DH. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol 1990; 108: 973-8.
128. Vander JF, Federman JL, Greven C, Slusher MM, Gabel VP. Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 1991; 98: 23-7.
129. Johnson MW, Olsen KR, Hernandez E. Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage. Ophthalmology 1992; 99: 515-21.
130. Ibanez HE, Williams DF, Thomas MA et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995; 113: 62-9.
131. Peyman GA, Nelson NC, Alturki W et al. Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 1991; 22: 575-82.
132. Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol 1997; 42: 195-213.
133. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994; 118: 559-68.
134. Kamei M, Tano Y, Maeno T, Ikuno Y, Mitsuda H, Yuasa T. Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 1996; 121: 267-75.
135. Lim JL, Drews-Botsch C, Sternberg P Jr., Capone A Jr., Aaberg TM Sr. Submacular hemorrhage removal. Ophthalmology 1995; 102: 1393-9.
136. Hassan AS, Johnson MW, Schneiderman TE et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999; 106: 1900-7.
137. Verma L, Das T, Binder S et al. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2000; 48: 263-78.
138. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999; 237: 273-7.
139. Ohji M, Saito Y, Hayashi A, Lewis JM, Tano Y. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998; 116: 1326-32.
140. Johnson MW, Olsen KR, Hernandez E, Irvine WD, Johnson RN. Retinal toxicity of recombinant tissue plasminogen activator in the rabbit. Arch Ophthalmol 1990; 108: 259-63.
141. Irvine WD, Johnson MW, Hernandez E, Olsen KR. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol 1991; 109: 718-22.
142. Hrach CJ, Johnson MW, Hassan AS, Lei B, Sieving PA, Elner VM. Retinal toxicity of commercial intravitreal tissue plasminogen activator solution in cat eyes. Arch Ophthalmol 2000; 118: 659-63.
143. Sternberg P Jr., Aguilar HE, Drews C, Aaberg TM. The effect of tissue plasminogen activator on retinal bleeding. Arch Ophthalmol 1990; 108: 720-2.
144. Thomas MA, Kaplan HJ. Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome. Am J Ophthalmol 1991; 111: 1-7.
145. Lambert HM, Capone A Jr., Aaberg TM, Sternberg P Jr., Mandell BA, Lopez PF. Surgical excision of subfoveal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 113: 257-62.
146. Berger AS, Kaplan HJ. Clinical experience with the surgical removal of subfoveal neovascular membranes. Short term postoperative results. Ophthalmology 1992; 99: 969-76.
147. Ormerod LD, Puklin JE, Frank RN. Long-term outcomes after the surgical removal of advanced subfoveal neovascular membranes in age-related macular degeneration. Ophthalmology 1994; 101: 1201-10.
148. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE, Dhaliwal RS. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994; 101: 1384-96.
149. Scheider A, Gundisch O, Kampik A. Surgical extraction of subfoveal choroidal new vessels and submacular hemorrhage in age-related macular degeneration: Results of a prospective study. Graefes Arch Clin Exp Ophthalmol 1999; 237: 10-15.
150. Merrill PT, LoRusso FJ, Lomeo MD, Saxe SJ, Khan MM, Lambert HM. Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 1999; 106: 782-9.
151. Lewis H, Vanderbrug Medendorp S. Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 1997; 104: 1847-52.
152. Gass JDM. Biomicroscopic and histopathologic consideration regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol 1994; 118: 285-98.
153. Nasir MA, Sugino I, Zarbin MA. Decreased choriocapillaris perfusion following surgical excision of choroidal neovascular membranes in age-related macular degeneration. Br J Ophthalmol 1997; 81: 481-9.
154. Del Priore LV, Kaplan HJ, Berger AS. Retinal pigment epithelial transplantation in the management of subfoveal choroidal neovascularization. Semin Ophthalmol 1997; 12: 45-55.
155. Hudson HL, Frambach DA, Lopez PF. Relation of the functional and structural fundus changes after submacular surgery for neovascular age-related macular degeneration. Br J Ophthalmol 1995; 79: 417-23.
156. Tsujikawa M, Sawa M, Lewis JM et al. Chorioretinal damage caused by the excision of choroidal neovascularization. Am J Ophthalmol 1998; 126: 348-57.
157. Algvere PV, Berglin L, Gouras P, Sheng Y. Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization. Graefes Clin Exp Ophthalmol 1994; 232: 707-16.
158. Gouras P, Algvere P. Retinal cell transplantation in the macula: New techniques. Vision Res 1996; 36: 4121-5.
159. Binder S, Krebs I, Feichtinger H et al. Outcome after transplantation of autologous retinal pigment epithelium in eyes with foveal CNV due to AMD: A non-randomized trial. In: The Association for Research in Vision and Ophthalmology Meeting 5-10 May 2002, Florida (CD-ROM). Rockville, MD: Association for Research in Vision and Ophthalmology, 2002. Available from http://www.arvo.org
160. Thumann G, Aisenbrey S, Schraermeyer U et al. Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes. Arch Ophthalmol 2000; 118: 1350-5.
161. Dintelmann TS, Heimann K, Kayatz P, Schraermeyer U. Comparative study of ROS degradation by IPE and RPE cells in vitro. Graefes Arch Clin Exp Ophthalmol 1999; 237: 830-9.
162. De Juan E Jr., Loewenstein A, Bressler NM, Alexander J. Translocation of the retina for management of subfoveal choroidal neovascularization II: A preliminary report in humans. Am J Ophthalmol 1998; 125: 635-46.
163. Fujikado T, Ohji M, Hayashi A, Kusaka S, Tano Y. Anatomic and functional recovery of the fovea after foveal translocation surgery without large retinotomy and simultaneous excision of a neovascular membrane. Am J Ophthalmol 1998; 126: 839-42.
164. Ninomiya Y, Lewis JM, Hasegawa T, Tano Y. Retinotomy and foveal translocation for surgical management of subfoveal choroial neovascular membranes. Am J Ophthalmol 1996; 122: 613-21.
165. Lindsey P, Finkelstein D, D'Anna S. Experimental retinal rotation. Invest Ophthalmol Vis Sci 1983; 24: S242.
166. Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 1993; 231: 635-41.
167. Wolf S, Lappas A, Weinberger AW, Kirchhof B. Macular translocation for surgical management of subfoveal choroidal neovascularizations in patients with AMD. First results. Graefes Arch Clin Exp Ophthalmol 1999; 237: 51-7.
168. Akduman L, Karavellas MP, MacDonald JC, Olk RJ, Freeman WR. Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration. Retina 1999; 19: 418-23.
169. Eckardt C, Eckardt U, Conrad HG. Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999; 237: 313-25.
170. Eckardt C. Further experience with 360-degree retinal rotation. In: Retina 2000. Management of Posterior Segment Disease at the American Academy of Ophthalmology Meeting. 20-21 October 2000. Dallas, Texas (CD-ROM). San
171. Pertile G, Claes C. Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization. Am J Ophthalmol 2002; 134: 560-5.
172. Au Eong KL, Pieramici DJ, Fujii GY et al. Macular translocation: Unifying concepts, terminology, and classification. Am J Ophthalmol 2001; 131: 244-53.
173. Lewis H, Kaiser PK, Lewis S, Estafanous M. Macular translocation for subfoveal choroidal neovascularization in age-related macular degeneration: A prospective study. Am J Ophthalmol 1999; 128: 135-46.
174. Pieramici DJ, De Juan E Jr., Fujii GY et al. Limited inferior macular translocation for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2000; 130: 419-28.
175. Haller JA, Hartranft CD, Fujii GY, Pieramici D, Humayun MS, De Juan E Jr. Limited macular translocation for neovascular maculopathy. Semin Ophthalmol 2000; 15: 81-8.
176. De Juan E Jr., Fujii GY. Limited macular translocation. Eye 2001; 15: 413-23.
177. Fujii GY, Pieramici DJ, Humayun MS et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000; 130: 751-62.
178. Lambert HM. The management of subfoveal choroidal neovascular membranes and hemorrhage. Semin Ophthalmol 2000; 15: 92-9.